AMS:PHARM - Pharming Group N.V Stock Price & Analysis

About Pharming Group N.V (AMS:PHARM)

(AMS:PHARM) Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII) for the treatment of haemophilia A; and protein replacement treatments for enzyme-deficiency disorders, such as pompe and fabry diseases, as well as products for acute kidney injury. The company has partnerships with China State Institute of Pharmaceutical Industry and the Chengdu Institute of Biological Products for the development of new products; and development collaboration and license agreement with Novartis to develop and commercialize leniolisib (CDZ173), a small molecule phosphoinositide 3-kinase delta inhibitor to treat patients with activated phosphoinositide 3-kinase delta syndrome. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

PHARM Stock Price

Statistics Highlights (AMS:PHARM)

Shares Outstanding	648.75M	Beta	1.58
Public Float	637.36M	P/E Ratio	32.73
% Short of Float	-	Dividend (Yield)	-
Held by Insiders	1.57%	Ex-Dividend Date
Held by Institutions	14.99%	IPO Date	-

Explore More on "Statistics" Section

PHARM Financial Summary

|

	Dec 21	Dec 20	Dec 19
Revenue	€167.68M	€185.69M	€169.02M
EBITDA	€41.22M	€51.07M	€63.77M
Net Income	€13.49M	€33.03M	€36.20M
Total Assets	€350.55M	€340.76M	€228.21M
Total Cash	€169.34M	€167.07M	€66.30M
Total Debt	€	€	€

	Dec 21	Sep 21	Jun 21
Revenue	€45.75M	€44.63M	€41.26M
EBITDA	€13.95M	€4.47M	€9.19M
Net Income	€1.86M	€-272.00K	€4.85M
Total Assets	€350.55M	€345.64M	€346.23M
Total Cash	€169.34M	€158.04M	€158.30M
Total Debt	€	€	€

PHARM Stock Price History

Pharming Group N.V Annual Stock Price History

Year	Open	Close	Change
2021	€0.77	€0.70	-9.35%
2021	€1.26	€0.77	-38.99%
2020	€1.59	€1.26	-20.40%

Pharming Group N.V Daily Stock Price History

Date	Open	High	Low	Close	Change	Volume
Jun 9, 2022	€0.77	€0.78	€0.76	€0.77	5.72%	2.66M
Jun 22, 2022	€0.72	€0.73	€0.71	€0.73	1.83%	1.66M
Jun 13, 2022	€0.73	€0.73	€0.71	€0.71	-5.51%	2.25M

View More on "Price History" Section

(AMS:PHARM) Stock Price FAQs

What is today's stock price of Pharming Group N.V (AMS:PHARM)?

The current stock price of Pharming Group N.V (AMS:PHARM) is €0.70.
Today PHARM stock price opened at €0.70 after previous close of €0.72.
During the day, Pharming Group N.V stock quote has varied from a low of €0.67 to a high of €0.71.

What is Pharming Group N.V's 52-week change?

PHARM 52-week high stock quote is €1.03, which is 47.90% above the current share price.
The Pharming Group N.V (AMS:PHARM) 52-week low stock price is €0.66, which is 5.80% below the current share price.
Pharming Group N.V share price volatility (52-week beta) is 1.58.

Pharming Group N.V (AMS:PHARM) FAQ

How Much is Pharming group n.v Worth?

Pharming group n.v's worth today based on market capitalisation is €467.10M

How much dividend does Pharming group n.v Pay?

The current annualized dividend payout for PHARM stock is €0.00, the dividend yield is 0.00% and the payout ratio is 0.00%.
View More Details on Pharming group n.v's "Dividend" Section

What is Pharming group n.v’s Price to Earning (PE) ratio?

Pharming group n.v has a Price to Earning (P/E) ratio of 32.73. PHARM stock also has a Price to Sales (P/S) ratio of 2.35, a Price to Book of 2.71 and Price/Earnings to Growth (PEG) of 0.00.

What is the Pharming group n.v's ticker?

Pharming group n.v trades on the Euronext Amsterdam stock market in Netherlands under the ticker symbol "PHARM". Pharming group n.v’s stock symbol can also be displayed as "AMS:PHARM".

Who are the owners of Pharming group n.v?

Pharming group n.v (AMS:PHARM) is owned by 14.99% institutional shareholders and by 1.57% insiders. The rest is owned by the public.
Explore More Details on Pharming group n.v's “Ownership” Section

Who are the key executives of Pharming group n.v (PHARM)?

Pharming group n.v's key executive team includes the following managers:

Dr. Sijmen de Vries M.B.A., M.D., MBA, Pres, CEO & Exec. Director (1959)
Dr. Bruno M. L. Giannetti, Consultant (1952)
Mr. Jeroen Wakkerman, Chief Financial Officer (1969)
Ms. Mireille Sanders M.Sc., Chief Operations Officer (1968)
Dr. Robert Friesen Ph.D., Chief Scientific Officer (1964)
Susanne Embleton, Investor Relations Mang. (NA)
Mr. Ruud Van Outersterp, Chief Ethics & Compliance Officer (1964)
Mr. Anurag Relan, Chief Medical Officer (1972)
Mr. Paul Th. Jansse, VP & Head of Non-US Commercial Operations (1969)
Mr. Stephen Toor, Chief Commercial Officer & GM of Americas (1971)

What is Pharming group n.v’s Sector & Industry Classification?

Pharming group n.v (AMS:PHARM) is classified under the "Healthcare" sector and under the "Biotechnology" industry.

How many employees work for Pharming group n.v?

Currently the number of employees working for Pharming group n.v is 277.

Where are Pharming group n.v's Headquarters?

Pharming group n.v (AMS:PHARM) is headquartered in Netherlands.

What are Pharming group n.v's Address and Phone Number?

Pharming group n.v’s mailing address is Darwinweg 24, Leiden, Netherlands, 2333 CR.
The company’s phone number is 31 71 524 7400.

What is the official website for Pharming group n.v?

Pharming group n.v’s official website is http://www.pharming.com

Pharming Group N.V Stock (AMS:PHARM)